Physician profile
Daqing Guo
NPI 1053388710
$1,265.35
in general payments reported to CMS, 2019-2025
15 companies · $1.66 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $339 · 2021: $57.46 · 2022: $2.13 · 2023: $59.58 · 2024: $19.27 · 2025: $1.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.98 · Education: $34.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.98 |
| Education | $34.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $240.29 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $189.91 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $172.64 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $170.94 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $133.16 | 2019-2023 | Lokelma |
| Novo Nordisk INC | $66.63 | 2019-2020 | |
| Fresenius USA Marketing, INC. | $59.14 | 2019-2020 | |
| Akebia Therapeutics INC | $50.87 | 2020 | |
| Vifor Pharma, INC. | $50.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $32.52 | 2019 | |
| Glaxosmithkline, LLC. | $30.86 | 2023 | Benlysta, Jesduvroq |
| Travere Therapeutics, INC. | $23.06 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $16.21 | 2020 | |
| Genzyme Corporation | $15.24 | 2019 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daqing Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.